MOTS-C

Metabolic / mitochondrial

Status

On watchlist — not yet prescribable

Mechanism

MOTS-C is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA. It regulates the folate cycle and de novo purine synthesis, activating AMPK and increasing insulin sensitivity. Plasma MOTS-C declines with age and in metabolic disease. It has demonstrated exercise-mimicking effects in rodent models.

Indications

→Insulin sensitivity and metabolic health

→AMPK activation (exercise-mimetic pathway)

→Mitochondrial function

→Obesity and metabolic syndrome research

Regulatory status

MOTS-C is a novel research peptide with no FDA approval and no established compounding status. It falls outside current 503A eligible lists. Northline monitors emerging regulatory frameworks.

References

01Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015.

02FDA 503A — not listed; ineligible for routine compounding.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.